Literature DB >> 21641651

Can effects of antidepressants in patients with mild depression be considered as clinically significant?

Ulrich Hegerl1, Antje-Kathrin Allgaier, Verena Henkel, Roland Mergl.   

Abstract

BACKGROUND: How to define clinical significance of antidepressants has become a matter of far-reaching clinical and regulatory consequences. A mean difference of at least 3 points on the Hamilton Depression Rating Scale (HAMD-17) between active treatment and placebo has been proposed as cut-off score for clinical significance in antidepressant trials.
OBJECTIVE: We aimed to present arguments that this, and other commonly used related approaches to establish clinical significance are likely to be misleading and risky depriving patients with mild depression of efficient treatments.
METHODS: These problems are exemplified with the data from a randomized placebo-controlled five-arm clinical trial with primary care patients with milder depressive syndromes (MIND-study). RESULTS AND
CONCLUSIONS: Designs for studying clinical significance have to be distinguished from those assessing efficacy. Moreover, evaluation of the clinical significance of psychotherapy as a possible alternative to antidepressants faces the problem of how to define a valid control group where blinding of neither therapists nor patients is possible.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21641651     DOI: 10.1016/j.jad.2011.05.015

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  7 in total

1.  Primary care physicians' and psychiatrists' approaches to treating mild depression.

Authors:  R E Lawrence; K A Rasinski; J D Yoon; K G Meador; H G Koenig; F A Curlin
Journal:  Acta Psychiatr Scand       Date:  2012-05-23       Impact factor: 6.392

2.  [Should treatment of mild depression be exclusively psychotherapeutic? Against].

Authors:  U Hegerl
Journal:  Nervenarzt       Date:  2013-03       Impact factor: 1.214

3.  Mirroring everyday clinical practice in clinical trial design: a new concept to improve the external validity of randomized double-blind placebo-controlled trials in the pharmacological treatment of major depression.

Authors:  Emanuel Severus; Florian Seemüller; Michael Berger; Sandra Dittmann; Michael Obermeier; Andrea Pfennig; Michael Riedel; Sophia Frangou; Hans-Jürgen Möller; Michael Bauer
Journal:  BMC Med       Date:  2012-07-02       Impact factor: 8.775

4.  Trends in the dispensation of antidepressant drugs over the past decade (2000-2010) in Andalusia, Spain.

Authors:  M C González-López; C M Rodríguez-López; T Parrón-Carreño; J D Luna; E Del Pozo
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2014-12-20       Impact factor: 4.328

5.  Not All Masks Are Created Equal: Masking Success in Clinical Trials of Children and Adolescents.

Authors:  Lauren Jones; Sarah R Black; L Eugene Arnold; Mary A Fristad
Journal:  J Clin Child Adolesc Psychol       Date:  2017-07-17

Review 6.  Risk assessment and predicting outcomes in patients with depressive symptoms: a review of potential role of peripheral blood based biomarkers.

Authors:  Bhautesh D Jani; Gary McLean; Barbara I Nicholl; Sarah J E Barry; Naveed Sattar; Frances S Mair; Jonathan Cavanagh
Journal:  Front Hum Neurosci       Date:  2015-02-02       Impact factor: 3.169

Review 7.  Should antidepressants be used in minor depression?

Authors:  Dieter Naber; Monika Bullinger
Journal:  Dialogues Clin Neurosci       Date:  2018-09       Impact factor: 5.986

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.